Sectors

TEVA
Teva Pharmaceutical Industries Limited
31.82
1 x 31.45
1 x 31.99
bid
ask
-
0.36
1.12%
30 @ 06:56 PM
32.19 +0.37 (1.16%)
Ytd1.95%
1y93.79%
31.66
day range
32.27
14.99
52 week range
37.35
Open32.04Prev Close32.18Low31.66High32.27Mkt Cap38.55B
Vol3.45MAvg Vol6.24MEPS1.34P/E24.71Forward P/E10.75
Beta0.86Short Ratio5.60Inst. Own62.45%DividendN/ADiv YieldN/A
Ex Div Date11-27Earning07-2950-d Avg34.20200-d Avg29.641yr Est40.90
Earning
DateForEstimateReportedSurprisesurprise %
2026-04-292026-030.50.530.036.00%
2026-01-282025-120.650.960.3147.69%
2025-11-052025-090.680.780.114.71%
2025-07-302025-060.630.660.034.76%
2025-05-072025-030.470.520.0510.64%
2025-01-292024-120.70.710.011.43%
Upgrade / Downgrade
DateFirmActionFromTo
2026-05-06BarclaysUpgradeOverweightOverweight
2026-04-30JP MorganUpgradeOverweightOverweight
2026-04-30UBSUpgradeBuyBuy
2026-04-30Piper SandlerUpgradeOverweightOverweight
2026-04-30Truist SecuritiesUpgradeBuyBuy
2026-04-09B of A SecuritiesUpgradeBuyBuy
Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Insider Holder
DateNameRelationQuantityDescription
2025-06-05CRANE ROSEMARY ADirector113.25KConversion of Exercise of derivative security
2026-03-02DANIELL RICHARDOfficer123.13KConversion of Exercise of derivative security
2025-06-05ELSTEIN AMIRDirector2.10MConversion of Exercise of derivative security
2026-03-04FRANCIS RICHARD DChief Executive Officer1.17MConversion of Exercise of derivative security
2026-03-04HUGHES ERIC AOfficer107.71KConversion of Exercise of derivative security
2026-03-04KALIF ELIYAHU SHARONChief Financial Officer325.44KConversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Blackrock Inc.65.14M2.16B5.59%
2026-03-30Harel Insurance Investments & Financial Services Ltd.45.96M1.52B3.95%
2026-03-30Phoenix Financial Ltd.42.78M1.42B3.67%
2026-03-30WCM Investment Management, LLC40.82M1.35B3.51%
2026-03-30Menora Mivtachim Holdings Ltd.39.63M1.31B3.40%
2026-03-30Clal Insurance Enterprises Holdings Ltd38.45M1.27B3.30%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30INVESTMENT MANAGERS SERIES TRUST-WCM Focused International Growth Fund13.25M438.83M1.14%
2026-05-30iShares Trust-iShares Core MSCI EAFE ETF8.65M286.38M0.74%
2026-03-30NEW ECONOMY FUND5.84M193.49M0.50%
2026-05-30Fidelity Contrafund5.22M172.90M0.45%
2026-04-29New World Fund Inc4.31M142.58M0.37%
2026-05-30Fidelity Concord Street Trust-Fidelity International Index Fund4.31M142.84M0.37%
Dividend
DividendDate
0.0852017-11-27
0.0852017-08-25
0.342017-06-01
0.342017-02-28
0.342016-12-01
0.342016-08-18
Split
SplitDate
2 : 12004-07-01
2 : 12002-12-06
2 : 12000-02-23
2 : 11993-04-14
1 : 11982-08-16